2664 related articles for article (PubMed ID: 31942075)
1. B cells and tertiary lymphoid structures promote immunotherapy response.
Helmink BA; Reddy SM; Gao J; Zhang S; Basar R; Thakur R; Yizhak K; Sade-Feldman M; Blando J; Han G; Gopalakrishnan V; Xi Y; Zhao H; Amaria RN; Tawbi HA; Cogdill AP; Liu W; LeBleu VS; Kugeratski FG; Patel S; Davies MA; Hwu P; Lee JE; Gershenwald JE; Lucci A; Arora R; Woodman S; Keung EZ; Gaudreau PO; Reuben A; Spencer CN; Burton EM; Haydu LE; Lazar AJ; Zapassodi R; Hudgens CW; Ledesma DA; Ong S; Bailey M; Warren S; Rao D; Krijgsman O; Rozeman EA; Peeper D; Blank CU; Schumacher TN; Butterfield LH; Zelazowska MA; McBride KM; Kalluri R; Allison J; Petitprez F; Fridman WH; Sautès-Fridman C; Hacohen N; Rezvani K; Sharma P; Tetzlaff MT; Wang L; Wargo JA
Nature; 2020 Jan; 577(7791):549-555. PubMed ID: 31942075
[TBL] [Abstract][Full Text] [Related]
2. Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Cabrita R; Lauss M; Sanna A; Donia M; Skaarup Larsen M; Mitra S; Johansson I; Phung B; Harbst K; Vallon-Christersson J; van Schoiack A; Lövgren K; Warren S; Jirström K; Olsson H; Pietras K; Ingvar C; Isaksson K; Schadendorf D; Schmidt H; Bastholt L; Carneiro A; Wargo JA; Svane IM; Jönsson G
Nature; 2020 Jan; 577(7791):561-565. PubMed ID: 31942071
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma.
Maibach F; Sadozai H; Seyed Jafari SM; Hunger RE; Schenk M
Front Immunol; 2020; 11():2105. PubMed ID: 33013886
[TBL] [Abstract][Full Text] [Related]
4. B cells are associated with survival and immunotherapy response in sarcoma.
Petitprez F; de Reyniès A; Keung EZ; Chen TW; Sun CM; Calderaro J; Jeng YM; Hsiao LP; Lacroix L; Bougoüin A; Moreira M; Lacroix G; Natario I; Adam J; Lucchesi C; Laizet YH; Toulmonde M; Burgess MA; Bolejack V; Reinke D; Wani KM; Wang WL; Lazar AJ; Roland CL; Wargo JA; Italiano A; Sautès-Fridman C; Tawbi HA; Fridman WH
Nature; 2020 Jan; 577(7791):556-560. PubMed ID: 31942077
[TBL] [Abstract][Full Text] [Related]
5. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.
De Henau O; Rausch M; Winkler D; Campesato LF; Liu C; Cymerman DH; Budhu S; Ghosh A; Pink M; Tchaicha J; Douglas M; Tibbitts T; Sharma S; Proctor J; Kosmider N; White K; Stern H; Soglia J; Adams J; Palombella VJ; McGovern K; Kutok JL; Wolchok JD; Merghoub T
Nature; 2016 Nov; 539(7629):443-447. PubMed ID: 27828943
[TBL] [Abstract][Full Text] [Related]
6. CD20
Wu Z; Zhou J; Xiao Y; Ming J; Zhou J; Dong F; Zhou X; Xu Z; Zhao X; Lei P; Huang T
Front Immunol; 2022; 13():865596. PubMed ID: 35634306
[TBL] [Abstract][Full Text] [Related]
7. Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies.
Trüb M; Zippelius A
Front Immunol; 2021; 12():674565. PubMed ID: 34054861
[TBL] [Abstract][Full Text] [Related]
8. Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas.
Edmonds NL; Gradecki SE; Katyal P; Lynch KT; Stowman AM; Gru AA; Engelhard VH; Slingluff CL; Mauldin IS
Oncoimmunology; 2023; 12(1):2164476. PubMed ID: 36632563
[TBL] [Abstract][Full Text] [Related]
9. A gene expression signature of TREM2
Xiong D; Wang Y; You M
Nat Commun; 2020 Oct; 11(1):5084. PubMed ID: 33033253
[TBL] [Abstract][Full Text] [Related]
10. Single-cell transcriptome sequencing of B-cell heterogeneity and tertiary lymphoid structure predicts breast cancer prognosis and neoadjuvant therapy efficacy.
Wang Q; Sun K; Liu R; Song Y; Lv Y; Bi P; Yang F; Li S; Zhao J; Li X; Chen D; Mei J; Yang R; Chen K; Liu D; Tang S
Clin Transl Med; 2023 Aug; 13(8):e1346. PubMed ID: 37525587
[TBL] [Abstract][Full Text] [Related]
11. Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer.
Sautès-Fridman C; Verneau J; Sun CM; Moreira M; Chen TW; Meylan M; Petitprez F; Fridman WH
Semin Immunol; 2020 Apr; 48():101406. PubMed ID: 33248905
[TBL] [Abstract][Full Text] [Related]
12. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
Auslander N; Zhang G; Lee JS; Frederick DT; Miao B; Moll T; Tian T; Wei Z; Madan S; Sullivan RJ; Boland G; Flaherty K; Herlyn M; Ruppin E
Nat Med; 2018 Oct; 24(10):1545-1549. PubMed ID: 30127394
[TBL] [Abstract][Full Text] [Related]
13. HLA-A
Zhang D; Jiang D; Jiang L; Ma J; Wang X; Xu X; Chen Z; Jiang M; Ye W; Wang J; Meng W; Qiu W; Hou Y; Huang J; Jiao Y; Liu Y; Liu Z
Br J Cancer; 2024 May; ():. PubMed ID: 38762674
[TBL] [Abstract][Full Text] [Related]
14. Spatial predictors of immunotherapy response in triple-negative breast cancer.
Wang XQ; Danenberg E; Huang CS; Egle D; Callari M; Bermejo B; Dugo M; Zamagni C; Thill M; Anton A; Zambelli S; Russo S; Ciruelos EM; Greil R; Győrffy B; Semiglazov V; Colleoni M; Kelly CM; Mariani G; Del Mastro L; Biasi O; Seitz RS; Valagussa P; Viale G; Gianni L; Bianchini G; Ali HR
Nature; 2023 Sep; 621(7980):868-876. PubMed ID: 37674077
[TBL] [Abstract][Full Text] [Related]
15. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts.
Rodriguez AB; Peske JD; Woods AN; Leick KM; Mauldin IS; Meneveau MO; Young SJ; Lindsay RS; Melssen MM; Cyranowski S; Parriott G; Conaway MR; Fu YX; Slingluff CL; Engelhard VH
Cell Rep; 2021 Jul; 36(3):109422. PubMed ID: 34289373
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients.
de Jonge K; Tillé L; Lourenco J; Maby-El Hajjami H; Nassiri S; Racle J; Gfeller D; Delorenzi M; Verdeil G; Baumgaertner P; Speiser DE
Oncoimmunology; 2021 Feb; 10(1):1873585. PubMed ID: 33643691
[TBL] [Abstract][Full Text] [Related]
17. Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy.
Vanmeerbeek I; Borras DM; Sprooten J; Bechter O; Tejpar S; Garg AD
Genes Immun; 2021 Jun; 22(2):108-119. PubMed ID: 34079092
[TBL] [Abstract][Full Text] [Related]
18. Single-Cell Transcriptomic Analysis Reveals a Tumor-Reactive T Cell Signature Associated With Clinical Outcome and Immunotherapy Response In Melanoma.
Yan M; Hu J; Ping Y; Xu L; Liao G; Jiang Z; Pang B; Sun S; Zhang Y; Xiao Y; Li X
Front Immunol; 2021; 12():758288. PubMed ID: 34804045
[TBL] [Abstract][Full Text] [Related]
19. B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies.
Willsmore ZN; Harris RJ; Crescioli S; Hussein K; Kakkassery H; Thapa D; Cheung A; Chauhan J; Bax HJ; Chenoweth A; Laddach R; Osborn G; McCraw A; Hoffmann RM; Nakamura M; Geh JL; MacKenzie-Ross A; Healy C; Tsoka S; Spicer JF; Papa S; Barber L; Lacy KE; Karagiannis SN
Front Immunol; 2020; 11():622442. PubMed ID: 33569063
[TBL] [Abstract][Full Text] [Related]
20. Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma.
Anagnostou V; Bruhm DC; Niknafs N; White JR; Shao XM; Sidhom JW; Stein J; Tsai HL; Wang H; Belcaid Z; Murray J; Balan A; Ferreira L; Ross-Macdonald P; Wind-Rotolo M; Baras AS; Taube J; Karchin R; Scharpf RB; Grasso C; Ribas A; Pardoll DM; Topalian SL; Velculescu VE
Cell Rep Med; 2020 Nov; 1(8):100139. PubMed ID: 33294860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]